USPTO serial 79405513
NORDICENDOTROPHIN
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- HACK, ANDREA R
- Law office
- TMEG LAW OFFICE 108
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with NORDICENDOTROPHIN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Diagnostic biomarker reagents for medical and clinical purposes; biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; biomarker assays to identify disease activity; biomarker assays to quantify disease activity; biomarker assays to analyse disease activity; diagnostic kits comprised of medical diagnostic reagents and assays for use in disease detection, disease analysis and quantifying disease activity; medical diagnostic agents; medical diagnostic reagents; clinical diagnostic agents; clinical diagnostic reagents; diagnostic preparations, substances and materials; medical diagnostic test strips; diagnostic preparations for medical purposes; diagnostic agents for medical use. | ACTIVE | — |
| 042 | Design and development of blood-based biomarker assays to identify, quantify and analyse disease activity; design and development of diagnostic biomarker reagents for medical, pharmaceutical, and scientific purposes; design and development of biochemical, pharmaceutical, and medical assays; design and development of biomarkers for use individually or in combination to detect tissue formation, tissue remodeling, or tissue destruction; scientific and pharmaceutical research in the field of biomarkers and biomarker discovery; identification of predictive and prognostic biomarkers for clinical trials; identifing patients for clinical trials most likely to respond to a given treatment using biomarkers; laboratory services relating to clinical trials; clinical trials; analysis of pharmacodynamic data; analysis of data relating to biomarkers; development of diagnostic preparations, equipment and tests; clinical testing services; diagnostic testing services; testing services relating to the detection and measurement of biomarkers; testing samples for the presence of biomarkers; laboratory services; medical laboratory services; research laboratory services; medical, pre-clinical, clinical, biological, biotechnological and pharmaceutical research, experimentation, development, and analysis; advice, information and assistance relating to the foregoing. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 27, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Oct 27, 2026 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Sep 24, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Mar 19, 2026 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Mar 2, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 2, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Oct 27, 2025 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Oct 27, 2025 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| May 4, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Apr 12, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Apr 12, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 7, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 6, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 27, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 8, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 8, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 3, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |